Marcia Belvin Sells 31,492 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Marcia Belvin sold 31,492 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $202,178.64. Following the sale, the senior vice president owned 300,760 shares of the company’s stock, valued at approximately $1,930,879.20. This trade represents a 9.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

CytomX Therapeutics Stock Down 6.9%

NASDAQ:CTMX opened at $4.45 on Friday. The company’s 50 day moving average is $5.28 and its 200-day moving average is $4.12. CytomX Therapeutics, Inc. has a 12 month low of $0.40 and a 12 month high of $8.21. The firm has a market cap of $757.35 million, a price-to-earnings ratio of -111.25 and a beta of 2.44.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.14). CytomX Therapeutics had a negative return on equity of 19.77% and a negative net margin of 22.79%.The firm had revenue of $0.66 million for the quarter, compared to the consensus estimate of $7.33 million. Research analysts predict that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

CytomX Therapeutics News Roundup

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Multiple high‑profile analyst upgrades and big price‑target increases (Jefferies, Barclays, Guggenheim, Wedbush and others) have pushed positive momentum and attracted buyers. Jefferies raises price target to $16
• Positive Sentiment: Trading volume spiked after the analyst upgrade cycle, suggesting the upgrades translated into real buying interest rather than just headlines. Strong trading volume after upgrades
• Neutral Sentiment: CytomX priced an equity offering to raise about $234 million, which materially extends runway and funding for the pipeline but will dilute existing shareholders. Timing and use of proceeds will determine the net effect. Equity offering announcement
• Neutral Sentiment: Short‑interest reports in recent filings show effectively zero reported short interest (data appears inconsistent/NaN), so short positioning is not clearly driving moves at this time. Short interest data (reporting)
• Negative Sentiment: CytomX missed Q1/quarterly estimates on both EPS and revenue, a concrete near‑term negative that increases uncertainty around execution and near‑term cash generation. Shares down on disappointing earnings
• Negative Sentiment: An analyst cut the Q1 EPS forecast, adding to concerns about near‑term financial performance and guidance. Q1 EPS forecast decreased
• Negative Sentiment: Clustered insider selling on March 17 (CEO Sean McCarthy, CFO Christopher Ogden, SVP Marcia Belvin and others) — sizable block sales by multiple senior executives — is dampening sentiment even if some sales are routine. Insider sales report
• Negative Sentiment: Some sell‑side and independent commentary warn that early clinical data may not yet justify elevated valuations, which could pressure momentum traders and cap further upside until clearer clinical/corporate catalysts arrive. Valuation caution commentary

Institutional Trading of CytomX Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC grew its stake in shares of CytomX Therapeutics by 4.5% during the fourth quarter. Squarepoint Ops LLC now owns 49,897 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 2,169 shares during the period. Wells Fargo & Company MN increased its holdings in CytomX Therapeutics by 83.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,000 shares during the last quarter. Velan Capital Investment Management LP lifted its stake in CytomX Therapeutics by 6.7% in the third quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biotechnology company’s stock valued at $255,000 after buying an additional 5,000 shares during the period. Farther Finance Advisors LLC acquired a new position in CytomX Therapeutics in the third quarter valued at about $25,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in CytomX Therapeutics during the fourth quarter worth about $35,000. 67.77% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. HC Wainwright raised their price target on CytomX Therapeutics from $10.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, March 16th. Guggenheim boosted their price objective on CytomX Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings downgraded CytomX Therapeutics from a “hold (c-)” rating to a “sell (d)” rating in a research note on Thursday. Barclays raised their target price on CytomX Therapeutics from $10.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday. Finally, Piper Sandler lifted their price target on CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, CytomX Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $13.22.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.